15 new development(s) in neoantigen vaccines today.
[COMPLETED · PHASE1 · Chinese PLA General Hospital] This is a single-center, open-label, non-randomized, parallel-group phase 1 study evaluating a personalized neoantigen-based dendritic cell vaccine following microwave ablation in patients with hepatocellular carcinoma. After re…
Background: The rising burden of metabolic dysfunction-associated steatotic liver disease (MASLD)-associated hepatocellular carcinoma (HCC) underscores the need for innovative therapeutic strategies. Methods: We integrated RNA-seq fusion detection, immunopeptidomics, and proteoge…
Test your knowledge with our new weekday mini crossword By Jason Mast, Matthew Herper, and Angus Chen Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Matthew Herper covers…
TOLEDO, Ohio (WTVG) - A new cancer vaccine is delivering hope in the fight against melanoma, the deadliest type of skin cancer. The vaccine is still undergoing trials, but results suggest it can stop the disease from coming back or spreading. The American Cancer Society says skin…
[NOT_YET_RECRUITING · PHASE1 · Shenzhen Geno-Immune Medical Institute] This study is designed to treat patients who have been diagnosed with brain cancer, including glioblastoma (GBM) and diffuse intrinsic pontine glioma (DIPG). The treatment uses immunomodulatory vaccine generat…
The personalized cancer vaccine being developed by Moderna and Merck has boosted hopes that mRNA technology could open up a new avenue of treatment, but the available evidence is still limited. Interim data from a large trial showed the experimental vaccine, when combined with M…
Merck and Moderna report positive phase III results for intismeran in melanoma, as The Medicine Maker revisits how cancer vaccines work and the challenges still facing the field A personalized mRNA cancer vaccine has delivered the first positive phase III readout for an individua…
Loizos Loizou, Head of Cyprus International Action Plan for Children with Cancer at ELPIDA Foundation for Children with Cancer, shared on LinkedIn: High-Risk Melanoma, Important New Hope: Personalized Therapeutic mRNA Vaccine. Melanoma is a particularly aggressive and dangerous s…
Adaptive Clinical Trial Design Adaptive Trial Design Addiction Psychiatry AI in Clinical Trials alcohol use disorder Alzheimer's Disease Article Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trial Quality C…
Intismeran autogene, an individualized neoantigen therapy, makes history on Wall Street as well as within the industry following its first positive Phase III data in a form of melanoma Investors of Merck & Co. (NYSE: MRK) and Moderna (Nasdaq: MRNA) were the most obvious—but not t…
Stéphane Bancel, Founding CEO at Moderna, shared an update from Moderna, on LinkedIn, adding: In 2020, mRNA helped change what was possible in infectious disease, as our teams worked to deliver a COVID-19 vaccine at unprecedented speed, in less than a year. Today, we announced th…
Merck and Moderna’s success with a personalized cancer vaccine designed to keep melanoma at bay opens a new avenue of treatment that doctors hope will work against many types of tumors. Unlike chemotherapy, which kills both healthy and cancerous cells, or immunotherapy, which re…
Subscribe to Smithsonian magazine and get a FREE tote. A personalized cancer vaccine, used in combination with an existing treatment, helped prevent the return and spread of melanoma in a late-stage clinical trial, Moderna and Merck, the companies developing the drug, announced t…
The experimental mRNA vaccine successfully cleared phase 3 clinical trials, the last step necessary before it can be approved by the FDA. An experimental mRNA cancer vaccine prevented the return and spread of melanoma, the deadliest form of skin cancer, in a large clinical trial,…
A breakthrough cancer vaccine developed by Moderna and Merck is fueling hopes that the next revolution in medicine could be as transformative as the arrival of antibiotics, organ transplants or the first targeted cancer drugs. Moderna and Merck announced this week that their Phas…